Therapeutic effect of Lactobacillus reuteri and Bifidobacterium bifidum on bronchopulmonary dysplasia based on 16S rDNA and metabonomics

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100048554

Enrollment

Unknown

Registered

2021-07-10

Start date

2021-07-01

Completion date

Unknown

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchopulmonary dysplasia

Interventions

Case series:No

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed as moderate or severe BPD; 2. Characterized by treatment with >21% oxygen for at least 28 days; 3. Oxygen support or positive pressure therapy required at 36 weeks after corrected gestational age.

Exclusion criteria

Exclusion criteria: 1. Early-onset sepsis; 2. Known congenital intestinal malformations or major malformations; 3. Referring patients; 4. Use H2 blockers, proton pump inhibitors, probiotics or immune agents.

Design outcomes

Primary

Measure	Time frame
Microbiome Deoxyribonucleic acid;	—

Countries

China

Contacts

Public ContactLi Ying

Central South University Third Xiangya Hospital

liying9771@126.com+86 13723857637

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026